On May 25, 2022 Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a developer of treatments for rare and orphan indications, including Parkinson Disease and various cancers, reported the clearance of the Phase 2 clinical trial protocol for mesothelioma after filing the protocol to the Food and Drug Administration (Press release, Oncotelic, MAY 25, 2022, View Source [SID1234615039]). Oncotelic is initiating a Phase 2 Investigator Initiated Study (IIS) clinical trial in patients with metastatic plural mesothelioma (MPM) in collaboration with Merck who is supplying pembrolizumab for the study.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The trial is titled M201: Phase 2 Trial of TGF-β Inhibition (OT-101) with Anti-PD-1 (pembrolizumab) in Patients with Malignant Pleural Mesothelioma (MPM) Failing to Achieve or Maintain Response to Checkpoint Inhibition. The trial is expected to enroll up to 63 patients across multiple centers in the U.S., including the center with the Principal Investigator – Melina Marmarelis, MD MSCE, Assistant Professor, Perelman School of Medicine, University of Pennsylvania, Medical Director of the University of Pennsylvania Pleural and Mesothelioma Center.
"This study encompasses a broad clinical strategy, which includes a robust and rigorous assessment of changes within the tumor microenvironment of various indications relative to pre and post therapy including the measurement of nearly 800 genes, spatial distribution of immune effector cells, expression of cytokines, phenotypic and functional changes, immunohistochemistry and deep sequencing in the hopes of better understanding the etiology and progression of malignancies and ultimately clinical benefit." noted Dr. Anthony E. Maida, Chief Clinical Officer – Translational Medicine, Oncotelic Therapeutics, Inc.
About M201
This is a phase 2, open label, non-randomized, single arm Simon’s two stage study in subjects with malignant pleural mesothelioma failing to achieve or maintain response to checkpoint inhibition. Before the efficacy assessment portion, the study will first embark a run-in dose-escalation phase to evaluate safety and tolerability of various dose of OT-101 in combination of pembrolizumab, and to determine a recommended Phase 2 dose (RP2D) of 4 days continuous i.v. infusion for every two weeks regimen. Subjects received the RP2D in the run-in dose-escalation phase will be part of the first stage of the Simon’s two-stage design for effectiveness evaluation.
A maximum of 63 subjects will be treated. Among them, a maximum of 30 subjects will be treated in the run-in dose-escalation phase to determine the MTD and RP2D. Thirty-nine subjects are required for the Simon’s two-stage assessment of efficacy: 19 subjects in the first stage, and 20 in the second stage. Subjects of the RP2D cohort in the run-in dose-escalation phase will be included in the first stage of the Simon’s two-stage assessment.
Primary Objective:
To determine whether the administration of TGF-β inhibitor (OT-101) in combination with pembrolizumab can provide improved tumor response (ORR) in MPM subjects that fail to achieve or maintain a response with anti-PD-1/PD-L1-based regimens.
Secondary Objectives:
1) To determine whether ORR induced by TGF-β inhibition combined with PD-1 blockade will result in an improved duration of response (DOR) and 6-month and 12-month Overall Survival (OS) and progression-free survival (PFS) as compared to current data with single agent pembrolizumab.
2) To evaluate the safety and tolerability of the administration of OT-101, in combination with pembrolizumab in patients with mesothelioma.
Exploratory Objective:
1) To determine whether TGF-β inhibition combined with PD-1 blockade will increase T cell infiltration, clonality in some tumors; and, the increased T cell infiltration, clonality (CD4, CD8 and Tregs) and IFN- λ signatures correlate with the reduced TBRS.
2) To determine if pretreatment TBRS signature is predictive of improved efficacy per ORR, DOR, and 6-month and 12-month overall survival OS, and progression free survival PFS.